Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity скачать в хорошем качестве

Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri speaks to ecancer about the primary progression-free survival analysis from the phase 3, randomised, open-label CONTACT-03 study. The study investigated the efficacy and safety of atezolizumab administered with cabozantinib as opposed to administering cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC). Dr Choueiri says the findings demonstrate that the addition of atezolizumab to cabozantinib did not improve clinical outcomes and that the progression-free survival was around 10-11 months in both arms of the trial. Moreover, the combination had higher toxicity compared to the control arm cabozantinib. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php